What is Claude Science and what can it do?

Claude Science is a new AI tool for medical research. Early examples show it spotted a viral contamination in minutes that a UCSF researcher's team had missed for a year, and it analyzed 100 rare genetic diseases in under an hour and flagged 32 candidates for computational screening.

How much could AI speed up drug development?

According to Novartis CEO Vas Narasimhan, AI tools could reduce information and operational latency—which make up roughly 40 percent of total development time—potentially bringing timelines from twelve years down to seven or eight years. They could also help double success rates from 8 to 16 percent through better safety predictions and optimized molecular properties.

Why is Anthropic entering drug discovery?

Anthropic says the move aligns with its nonprofit mission and will help it build better AI models and tools for the broader industry through firsthand experience in drug development for diseases that traditional pharma and biotech firms consider unprofitable.

AI in HealthcareAI Business & IndustryTHE DECODERJul 4, 2026Jul 4, 2026, 19:00 JST2 min read

Anthropic launches drug discovery programs for neglected diseases

Send on LINE

Key takeaway

Anthropic is launching its own drug discovery programs for neglected diseases that large pharmaceutical firms deem unprofitable, positioning the move as consistent with its nonprofit mission.
The company also released Claude Science, an AI research tool that can accelerate drug development by reducing information and operational delays—which account for roughly 40 percent of typical development timelines.
Novartis's CEO indicated that AI could shorten development cycles from twelve years to seven or eight years and potentially double success rates, though experts caution that clinical applications of AI still require careful oversight.

3 Key Points

What happened
Anthropic announced it is launching its own drug discovery programs targeting neglected diseases that traditional pharma and biotech firms consider unprofitable. The company will focus on early, preclinical-stage drug development. Anthropic also unveiled Claude Science, a new AI tool for research, and demonstrated early examples including a UCSF researcher using it to spot a viral contamination in minutes that his team had missed for an entire year.
Why it matters
Pharma R&D timelines and success rates have long been constrained by information delays and operational bottlenecks. Novartis CEO Vas Narasimhan stated that AI tools could cut information and operational latency—which account for roughly 40 percent of total development time—potentially bringing drug development timelines down from twelve years to seven or eight years. Even modest improvements would matter: major pharma companies spend $150 to $200 billion（約32兆円） a year on R&D, and expanding the pool of treatable diseases could make previously unreachable drug targets viable.
What to watch
Claude Science analyzed 100 rare genetic diseases in under an hour and flagged 32 candidates for computational screening. Anthropic frames this drug discovery work as aligned with its nonprofit mission and as a way to build better AI models through firsthand experience in the sector. Other AI firms—including Deepmind (via Isomorphic Labs with Alphabet) and OpenAI—are also expanding into medicine and clinical tools.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Get news like this every morning — free

FAQ

What is Claude Science and what can it do?: Claude Science is a new AI tool for medical research. Early examples show it spotted a viral contamination in minutes that a UCSF researcher's team had missed for a year, and it analyzed 100 rare genetic diseases in under an hour and flagged 32 candidates for computational screening.
How much could AI speed up drug development?: According to Novartis CEO Vas Narasimhan, AI tools could reduce information and operational latency—which make up roughly 40 percent of total development time—potentially bringing timelines from twelve years down to seven or eight years. They could also help double success rates from 8 to 16 percent through better safety predictions and optimized molecular properties.
Why is Anthropic entering drug discovery?: Anthropic says the move aligns with its nonprofit mission and will help it build better AI models and tools for the broader industry through firsthand experience in drug development for diseases that traditional pharma and biotech firms consider unprofitable.

THE DECODERRead Original Article

Send on LINE